Skip to main
DVAX
DVAX logo

Dynavax Technologies (DVAX) Stock Forecast & Price Target

Dynavax Technologies (DVAX) Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 25%

Bulls say

Dynavax Technologies Corp demonstrates strong potential due to the promising vaccine response rates (VRR) of its 100ug dose, which are comparable to the established Shingrix vaccine, paired with significantly better tolerability. Furthermore, the company shows encouraging results in CD4+ T-cell responses for its Z-1018 shingles vaccine candidate, indicating robust immunogenicity and safety profiles that align with management's objectives. This positive data from Dynavax's ongoing product development and pipeline enhancements strengthens the outlook for the company's future revenue generation from its vaccine portfolio, primarily driven by CpG 1018 and HEPLISAV-B.

Bears say

Dynavax Technologies Corp faces significant risks in its clinical development pipeline, with the potential for future candidates to fail efficacy endpoints or present safety concerns that could hinder approvals and commercialization. The company may struggle to effectively bring its proprietary candidates to market due to unfavorable market conditions, strong competition, and internal challenges, which could further exacerbate revenue generation issues. Additionally, the uncertainty surrounding potential partnerships for its candidates adds another layer of risk, as unsuccessful negotiations could jeopardize the success of their commercial launches.

Dynavax Technologies (DVAX) has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 25% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dynavax Technologies (DVAX) Forecast

Analysts have given Dynavax Technologies (DVAX) a Hold based on their latest research and market trends.

According to 4 analysts, Dynavax Technologies (DVAX) has a Hold consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dynavax Technologies (DVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.